BioMarin Pharmaceutical Inc. (BMRN) Financial Statements (2025 and earlier)

Company Profile

Business Address 105 DIGITAL DRIVE
NOVATO, CA 94949
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,224,3511,046,5801,073,8101,125,8451,170,9581,152,091
Cash and cash equivalents972,150746,996755,127785,414694,381580,074
Short-term investments252,201299,584318,683340,431476,577572,017
Receivables691,232637,163633,704572,498610,222597,913
Inventory, net of allowances, customer advances and progress billings1,183,6211,137,9821,107,1831,032,159975,546918,921
Inventory1,183,6211,137,9821,107,1831,032,159975,546918,921
Other current assets160,426163,287141,391224,806193,391173,180
Total current assets:3,259,6302,985,0122,956,0882,955,3082,950,1172,842,105
Noncurrent Assets
Property, plant and equipment1,052,8981,060,4251,066,1331,067,1561,067,2781,068,142
Long-term investments and receivables557,083620,551611,135548,002385,777340,635
Long-term investments557,083620,551611,135548,002385,777340,635
Intangible assets, net (including goodwill)461,732475,852490,900498,675506,542522,188
Goodwill196,199196,199196,199196,199196,199196,199
Intangible assets, net (excluding goodwill)265,533279,653294,701302,476310,343325,989
Deferred income tax assets1,545,0061,546,0431,545,8091,523,9531,509,2901,510,568
Other noncurrent assets190,772184,790171,538165,069144,168150,057
Total noncurrent assets:3,807,4913,887,6613,885,5153,802,8553,613,0553,591,590
TOTAL ASSETS:7,067,1216,872,6736,841,6036,758,1636,563,1726,433,695
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:572,500593,543683,147669,825597,231598,231
Accrued liabilities174,268164,738218,017198,749155,069171,556
Other undisclosed accounts payable and accrued liabilities398,232428,805465,130471,076442,162426,675
Debt 494,837494,357493,877493,398  
Total current liabilities:1,067,3371,087,9001,177,0241,163,223597,231598,231
Noncurrent Liabilities
Long-term debt and lease obligation594,116593,605593,095592,5861,084,9941,084,006
Long-term debt, excluding current maturities594,116593,605593,095592,5861,084,9941,084,006
Liabilities, other than long-term debt119,369117,352119,935105,45798,12092,415
Other liabilities119,369117,352119,935105,45798,12092,415
Total noncurrent liabilities:713,485710,957713,030698,0431,183,1141,176,421
Total liabilities:1,780,8221,798,8571,890,0541,861,2661,780,3451,774,652
Equity
Equity, attributable to parent, including:5,286,2995,073,8164,951,5494,896,8974,782,8274,659,043
Common stock190190189188188188
Additional paid in capital5,696,7015,619,2645,611,5625,542,7745,493,9565,417,873
Accumulated other comprehensive income (loss)26,799(1,046)(28,788)6,257(18,617)(10,722)
Accumulated deficit(425,718)(532,892)(621,554)(641,929)(682,307)(738,347)
Other undisclosed equity, attributable to parent(11,673)(11,700)(9,860)(10,393)(10,393)(9,949)
Total equity:5,286,2995,073,8164,951,5494,896,8974,782,8274,659,043
TOTAL LIABILITIES AND EQUITY:7,067,1216,872,6736,841,6036,758,1636,563,1726,433,695

Income Statement (P&L) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Revenues712,029648,833646,207581,329595,275596,415
Cost of revenue(130,459)(125,180)(135,478)(124,745)(128,082)(126,549)
Gross profit:581,570523,653510,729456,584467,193469,866
Operating expenses(461,118)(435,191)(481,274)(415,242)(392,699)(394,849)
Other undisclosed operating loss   (15,236)(15,681)(15,624)(15,670)
Operating income:120,45288,46214,21925,66158,87059,347
Nonoperating income
(Investment Income, Nonoperating)
19,78519,36518,04415,74012,61211,943
Interest and debt expense(3,574)(3,547)(6,098)(3,779)(3,755)(3,703)
Income from continuing operations before equity method investments, income taxes:136,663104,28026,16537,62267,72767,587
Other undisclosed income (loss) from continuing operations before income taxes(4,527)1,267(6,838)4,0473,083(10,830)
Income from continuing operations before income taxes:132,136105,54719,32741,66970,81056,757
Income tax expense (benefit)(24,962)(16,885)1,048(1,291)(14,770)(5,905)
Net income available to common stockholders, basic:107,17488,66220,37540,37856,04050,852
Interest on convertible debt2,7692,769  937937
Other undisclosed net loss available to common stockholders, diluted   (2,810)   
Net income available to common stockholders, diluted:109,94391,43117,56540,37856,97751,789

Comprehensive Income ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net income:107,17488,66220,37540,37856,04050,852
Comprehensive income:107,17488,66220,37540,37856,04050,852
Other undisclosed comprehensive income (loss), net of tax, attributable to parent27,84527,742(35,045)24,874(7,895)(6,855)
Comprehensive income (loss), net of tax, attributable to parent:135,019116,404(14,670)65,25248,14543,997

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: